Sarepta Therapeutics (NASDAQ:SRPT) Research Coverage Started at Wedbush

Wedbush initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Tuesday, Marketbeat.com reports. The brokerage issued an outperform rating and a $32.00 price objective on the biotechnology company’s stock.

A number of other equities analysts have also commented on SRPT. Weiss Ratings reissued a “sell (d-)” rating on shares of Sarepta Therapeutics in a research note on Monday, November 24th. Barclays cut their price target on Sarepta Therapeutics from $22.00 to $20.00 and set an “equal weight” rating for the company in a report on Wednesday, November 5th. Bank of America increased their price objective on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an “underperform” rating in a report on Wednesday, October 22nd. Guggenheim lowered their price objective on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Finally, Royal Bank Of Canada boosted their target price on shares of Sarepta Therapeutics from $14.00 to $16.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 8th. Nine analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have given a Sell rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Hold” and a consensus price target of $33.68.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT opened at $21.75 on Tuesday. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. The firm has a market cap of $2.28 billion, a PE ratio of -7.23 and a beta of 0.54. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $129.84. The company’s 50-day moving average price is $20.95 and its two-hundred day moving average price is $21.22.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.15). The firm had revenue of $399.36 million for the quarter, compared to analyst estimates of $331.51 million. Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.The business’s quarterly revenue was down 14.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.62 EPS. On average, equities analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Inspire Investing LLC acquired a new stake in Sarepta Therapeutics in the first quarter valued at $967,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Sarepta Therapeutics by 54.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 463,342 shares of the biotechnology company’s stock valued at $29,570,000 after buying an additional 164,041 shares during the last quarter. Tempus Wealth Planning LLC increased its stake in shares of Sarepta Therapeutics by 475.8% in the second quarter. Tempus Wealth Planning LLC now owns 20,658 shares of the biotechnology company’s stock valued at $353,000 after buying an additional 17,070 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Sarepta Therapeutics by 21.8% during the second quarter. Assenagon Asset Management S.A. now owns 867,939 shares of the biotechnology company’s stock worth $14,842,000 after acquiring an additional 155,358 shares during the last quarter. Finally, Trexquant Investment LP bought a new position in shares of Sarepta Therapeutics during the first quarter worth about $11,997,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.